Press release

Press release

March 17, 2016

Resolution to conduct a rights issue

On 15 March, board of directors of Follicum AB (publ) resolved to carry out a rights issue of 6 001 938 shares at an issue price of 5.00 SEK per share. At full subscription, this will raise approximately 30 MSEK of additional capital, before rights issue costs. The rights issue resolution of the board of […]

March 15, 2016

Positive results from Phase I of Follicum’s phase I/IIa clinical study reported

In early January 2016,  Follicum announced that the first healthy volunteer in the company’s clinical phase I/IIa study showed no negative effects after receiving the maximum dosage of FOL-005. Nine further healthy volunteers have now been given with the maximum dose and show the same positive results. This completes the first part of the phase […]

March 11, 2016

Follicum receives Allowance for Patent in the USA

On 10 March 2016 Follicum received a Notice of Allowance from the US Patent and Trademark Office regarding the patent application entitled “Novel Compositions and Uses Thereof”. The Notice of Allowance concerns the application for the lead drug candidate FOL-005 and related substances. The patent term lasts until at least 2032, with the possibility for […]

February 3, 2016

Maximum dose level achieved, in clinical phase I/IIa study, without complications

The maximum dose level in Follicum’s clinical phase I/IIa study has now been administered to the first healthy volunteer without any negative effects being seen, achieving the study’s initial dose escalating part without any problems. The clinical study was initiated on 19 January 2016. The first participant in the study was administered with the maximum […]

January 22, 2016

Follicum Announces First Healthy Volunteer Dosed With FOL-005

On 19 January 2016 the first healthy volunteer received treatment with FOL-005, initiating the clinical phase I/IIa safety/efficacy study according to Follicum’s previously communicated time plan. Previously FOL-005 has shown effective inhibition of hair growth on living human skin tissue in vitro but this is the first time it has been used in man. Treatment of around […]

December 16, 2015

Approval to Start Clinical Study

Today Follicum obtained approval from the BfArM (the Federal Institute for Drugs and Medical Devices in Germany) and the research ethics committee to start a clinical Phase I/II a study. The study will now proceed according to the previously communicated plan. The study will be performed by the Clinical Research Center for Hair and Skin […]

November 30, 2015

Interim Report Q3 2015

Follicum today reported publication of its Q3 2015 interim report in Swedish. Below is a short summary of activities during the period: Significant activities during third quarter 2015: -On 1 September the company announced that the two toxicity studies which had been ongoing since March were completed, showing positive results. -In September Follicum initiated a collaboration […]

November 23, 2015

99.36% of Follicum’s TO 1 warrants converted

The utilization period of the TO 1 series warrants issued in conjunction with Follicum’s initial public offering ended on 17 November, warrants were converted at a rate of 99.36%. This provides additional funding of about 6.96 MSEK before issuing costs to Follicum. For more information, please contact Jan Alenfall, CEO Tel +46 (0) 46 19 […]

October 26, 2015

Information about warrants

Tomorrow, October 27, 2015, the utilization period of the series TO 1 warrants issued in conjunction with Follicum’s initial public offering starts. The utilization period will run until November 17, 2015. Warrant holders are entitled to subscribe for one new share in Follicum for each warrant at a price of SEK 6.00 per share. For more […]